What does 'revolutionize' actually mean? The gap between response and remission
The term 'revolutionize' can be misleading. Biologics are powerful, but they don't work equally for everyone. The most ambitious goal is 'clinical remission'—defined as zero asthma attacks, no need for oral corticosteroids, normal lung function, and well-controlled symptoms for at least 12 months [1][2][5]. In the largest real-world studies, only 18-29% of patients achieve this strict definition after one year of biologic therapy [1][2][3]. For example, the Danish Severe Asthma Register found that 79% of patients had a clinical response (fewer attacks or lower steroid dose), but only 19% met the full remission criteria [1]. Similarly, the UK Severe Asthma Registry reported 18.3% remission [2], and Australian registries found 23-29% depending on the biologic used [3]. So while most patients improve, full remission is the exception, not the rule.
Why the gap? Many patients who respond still have lingering symptoms. A French real-life study found that physicians considered 88% of biologic-treated patients to be 'responders,' yet only 25% had controlled asthma based on symptom questionnaires [4]. The main culprits were untreated comorbidities like gastroesophageal reflux disease (GERD) and obstructive sleep apnea (OSA), which independently predicted poor control [4]. This means biologics are revolutionary for reducing severe attacks and steroid use, but they don't fix everything—and other health issues must be addressed simultaneously.
Who gets the best results? Timing and patient profile matter enormously
The evidence consistently shows that biologics work best in patients with 'type 2 high' asthma—characterized by high blood eosinophils or high IgE levels. In the UK registry, patients with type 2 biomarkers had 7.4 times higher odds of achieving remission compared to those without [2]. But even within this group, success depends on starting treatment early. Every 10-year increase in disease duration reduced the likelihood of remission by 14% [2]. Shorter disease duration and lower body mass index (BMI) also predicted better outcomes across multiple studies [1][3]. This suggests that waiting too long to start biologics may allow irreversible airway damage to accumulate, making remission harder to reach.
Age and comorbidities also play a role. Elderly patients (over 70) can use biologics safely, with mostly mild side effects, but they often have more complex health issues [8]. Children also benefit: pediatric studies show biologics reduce severe asthma attacks by 40-70% and improve quality of life, though remission rates in kids are less studied [7][11]. The key takeaway: biologics are most revolutionary when given to the right patient at the right time—ideally early in the disease course, before obesity and other conditions complicate management.
What happens when one biologic isn't enough? Switching and combining therapies
Not everyone responds to their first biologic. About 21% of patients show no clinical response after 12 months [1]. In those cases, switching to a different biologic can help. Real-world data show that patients who switch—often from omalizumab to an anti-IL5 drug like mepolizumab—tend to have higher baseline eosinophil counts and more exacerbations, and many improve after the switch [9]. The choice of which biologic to switch to is guided by biomarkers (eosinophils, FeNO) and comorbidities like nasal polyps [9][10].
For a small subset with very severe or multi-pathway disease, combining two biologics is an emerging strategy. A case series of 10 patients on dual therapy (e.g., mepolizumab plus dupilumab) showed good tolerance and improvements in asthma control and steroid reduction, with no serious adverse events [6]. However, this is still experimental—only studied in a handful of patients—and long-term safety is unknown. So while biologics have revolutionized options, the revolution is still ongoing: we're learning how to personalize and combine them for the toughest cases.
About These Sources
This answer is built on 11 peer-reviewed studies — published from 2021 to 2025, 3 from 2024 or later, 6 in Q1 journals, collectively cited 412 times — selected as the most relevant from 15 studies that passed quality screening, drawn from 57 papers retrieved from a database of over 500 million.
Sources used in this answer
Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies
In a nationwide Danish cohort of 501 patients, 79% had a clinical response after 12 months of biologic therapy, but only 19% achieved full clinical remission; shorter disease duration and lower BMI predicted remission.
Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry
In the UK Severe Asthma Registry (n=~1,000), 18.3% achieved clinical remission; type 2-high biomarkers increased odds of remission 7.4-fold, while female sex, obesity, and longer disease duration reduced odds.
Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients
In Australian registries, 29.3% of mepolizumab-treated and 22.8% of omalizumab-treated patients achieved clinical remission; better lung function, lower BMI, and absence of comorbidities predicted success.
Improvement in severe asthma patients receiving biologics and factors associated with persistent insufficient control: a real-life national study
In a French real-life study of 431 patients, physicians rated 88% as biologic responders, but only 25.3% had controlled asthma by ACQ; GERD and sleep apnea were independent predictors of poor control.
The role of biologics in inducing remission in asthma
A review article defines asthma remission as no symptoms, no exacerbations, no systemic steroids, and stable lung function for ≥1 year; biologics achieve remission in 20-35% of treated patients.
Combining Dual Biologics Therapy for Severe Asthma: A Series of Ten Cases
A case series of 10 patients on dual biologics (e.g., mepolizumab+dupilumab) showed good tolerance and improved asthma control and OCS reduction, with no serious adverse events reported.
Biologics and severe asthma in children
A review of pediatric biologics reports that randomized trials show 40-70% reduction in severe exacerbations in children, with improvements in lung function and quality of life, and reassuring safety profiles.
Safety of biological therapy in elderly patients with severe asthma
In 21 elderly patients (>70 years) on biologics, 42.9% had mild adverse events; one case of anaphylaxis occurred with omalizumab, but overall treatment was deemed safe.
Switching Biological Therapies in Severe Asthma
A review of biologic switching in severe asthma finds that patients switched from omalizumab due to poor control often have higher eosinophils and exacerbation rates; the choice of next biologic is guided by biomarkers and comorbidities.
Biologics for severe asthma and beyond
A review of six approved biologics for severe asthma concludes they reduce exacerbations and OCS use, improve control and lung function, and can induce remission in a subset; selection depends on phenotype and biomarkers.
Biologic Therapies for Severe Asthma in School-Age Children.
A 2025 review of pediatric biologics (omalizumab, mepolizumab, benralizumab, dupilumab) for ages 6-11 reports 27-59% reduction in exacerbations vs. placebo, with reassuring safety; selection is biomarker-driven.